Guidance for resumption of routine electrodiagnostic testing during the COVID-19 pandemic.
Urvi DesaiCharles D KassardjianDavid Del ToroNida Gleveckas-MartensJayashri SrinivasanDeborah VenesyPushpa Narayanaswaminull nullPublished in: Muscle & nerve (2020)
As the world accommodates to the coronavirus disease 2019 (COVID-19) pandemic, routine in-person medical services are resuming. The resumption of non urgent electrodiagnostic (EDX) testing faces unique challenges due to the long duration of the procedure and direct close contact with patients, including studies with risk of exposure to oropharyngeal secretions. We provide consensus guidance for resumption of EDX testing, addressing scheduling, patient arrival and registration, use of personal protective equipment, COVID-19 screening and testing, the performance of EDX testing in outpatient and inpatient settings, cleaning and maintenance of the EDX equipment and laboratory, balancing trainee safety and training requirements, and patient care issues. These are broad recommendations that need to be adapted to local COVID-19 risks, institutional guidelines and policies, and changing federal, state, and local regulations, and to changes in the pandemic over time.
Keyphrases
- coronavirus disease
- sars cov
- clinical practice
- healthcare
- end stage renal disease
- chronic kidney disease
- mental health
- respiratory syndrome coronavirus
- newly diagnosed
- primary care
- palliative care
- minimally invasive
- ejection fraction
- prognostic factors
- climate change
- patient reported
- patient reported outcomes
- case control
- acute care